37. Generalised pustular psoriasis
[
29 clinical trials,
34 drugs（DrugBank:
15 drugs),
16 target genes / 88 target pathways ]
Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03885089 | November 30, 2019 | 22 October 2019 | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis) | Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis) | Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic Psoriasis | Drug: Infliximab [infliximab biosimilar 3] | Pfizer | Not recruiting | N/A | N/A | All | 100 | Phase 2 | Japan | |
| 2 | NCT03998683 | September 3, 2019 | 11 November 2019 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Psoriasis | Drug: Guselkumab 100 mg;Drug: Placebo | Janssen-Cilag Ltd. | Recruiting | 18 Years | N/A | All | 105 | Phase 3 | France;Germany;Italy;Spain;United Kingdom | |
| 3 | NCT03942042 | July 4, 2019 | 2 September 2019 | A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | Generalized Pustular Psoriasis;Erythrodermic Psoriasis | Drug: Ixekizumab | Eli Lilly and Company | Recruiting | 20 Years | N/A | All | 12 | Phase 4 | Japan | |
| 4 | NCT03886246 | May 27, 2019 | 4 November 2019 | A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130 | An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP) | Generalized Pustular Psoriasis | Drug: Spesolimab | Boehringer Ingelheim | Recruiting | 18 Years | N/A | All | 120 | Phase 3 | United States;France;Malaysia;Taiwan | |
| 5 | NCT03619902 | March 4, 2019 | 15 July 2019 | A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis | A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | Drug: ANB019 | AnaptysBio, Inc. | Recruiting | 18 Years | 75 Years | All | 10 | Phase 2 | United States;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2017-004231-37-FR | 22/01/2019 | 28 February 2019 | A study to test BI 655130 in patients with a flare-up of a skin disease called Generalized Pustular Psoriasis | Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity. - Flare Treatment Phase II Trial in GPP | Generalized Pustular Psoriasis (GPP) MedDRA version: 20.0 Level: LLT Classification code 10037159 Term: Psoriasis pustular System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: BI 655130 Pharmaceutical Form: Solution for infusion INN or Proposed INN: BI 655130 CAS Number: *MASKED* Current Sponsor code: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Boehringer Ingelheim France | Authorised | Female: yes Male: yes | 27 | Phase 2 | United States;France;Taiwan;Malaysia;Thailand;Singapore;Germany;Tunisia;Japan;Switzerland | |||
| 7 | JPRN-jRCTs031180367 | 20/02/2018 | 10 September 2019 | The effect of infliximab on endothelial function in patients with psoriasis | A pilot study for the effect of infliximab on endothelial function in patients with psoriasis | Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis;D011565, D015535 | Endothelial function is measured in patients with psoriasis treated with infliximab before and after the first, second, and third infusions. | YOSHIHIDE ASANO | Recruiting | >= 20age old | < 80age old | Both | 25 | N/A | none | |
| 8 | JPRN-UMIN000027208 | 2017/06/01 | 2 April 2019 | A pilot study for the effect of infliximab on endothelial function in patients with psoriasis | Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis | Endothelial function is measured in patients with psoriasis treated with infliximab before and after the first, second, and third infusions. | The University of Tokyo Hospital | Recruiting | 20years-old | 80years-old | Male and Female | 25 | Not applicable | Japan | ||
| 9 | NCT03051217 | February 21, 2017 | 4 February 2019 | A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis | Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis | Moderate to Severe Psoriasis;Generalized Pustular Psoriasis and Erythrodermic Psoriasis | Other: Placebo;Drug: Certolizumab Pegol | UCB Biopharma S.P.R.L. | Not recruiting | 20 Years | N/A | All | 149 | Phase 2/Phase 3 | Japan | |
| 10 | NCT03022045 | January 26, 2017 | 11 June 2018 | A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Generalized Pustular Psoriasis;Erythrodermic Psoriasis | Drug: risankizumab | AbbVie | Not recruiting | 20 Years | N/A | All | 17 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02978690 | December 19, 2016 | 29 January 2018 | BI655130 Single Dose in Generalized Pustular Psoriasis | Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis. | Psoriasis | Drug: BI655130 | Boehringer Ingelheim | Not recruiting | 18 Years | 75 Years | All | 7 | Phase 1 | France;Japan;Korea, Republic of;Malaysia;Taiwan;Tunisia;Singapore | |
| 12 | EUCTR2015-003600-23-GB | 01/04/2016 | 30 April 2018 | Comparing Anakinra versus placebo in the treatment of pustular psoriasis | Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies | Acral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study. MedDRA version: 20.0 Level: PT Classification code 10037575 Term: Pustular psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Anakinra Product Name: Anakinra Pharmaceutical Form: Solution for injection INN or Proposed INN: ANAKINRA CAS Number: 143090-92-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Guy's and St Thomas NHS Foundation Trust | Authorised | Female: yes Male: yes | 64 | Phase 4 | United Kingdom | |||
| 13 | NCT02533375 | September 28, 2015 | 16 December 2017 | Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis | Generalized Pustular Psoriasis (GPP);Adalimumab;Japanese | Drug: Adalimumab | AbbVie | Not recruiting | 15 Years | 75 Years | All | 10 | Phase 3 | Japan | |
| 14 | NCT02343744 | January 19, 2015 | 4 November 2019 | An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Pustular Psoriasis | Drug: Guselkumab | Janssen Pharmaceutical K.K. | Not recruiting | 20 Years | N/A | All | 21 | Phase 3 | Japan | |
| 15 | JPRN-JapicCTI-142430 | 01/2/2014 | 2 April 2019 | A Phase 3 Clinical Study of KHK4827 | An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null | Kyowa Hakko Kirin Co., Ltd. | 18 | BOTH | 165 | Phase 3 | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02052609 | February 2014 | 4 November 2019 | A Phase 3 Clinical Study of KHK 4827 | An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythroderma | Drug: KHK4827 140mg SC;Drug: KHK4827 210mg SC | Kyowa Kirin Co., Ltd. | Not recruiting | 18 Years | N/A | All | 155 | Phase 3 | Japan | |
| 17 | NCT02008890 | December 26, 2013 | 14 January 2019 | Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab | A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks | Palmoplantar Pustular Psoriasis | Biological: Secukinumab 300mg;Biological: Secukinumab 150mg;Biological: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 237 | Phase 3 | Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom | |
| 18 | EUCTR2013-003086-34-SE | 04/12/2013 | 2 October 2017 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis | Moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 16.1 Level: PT Classification code 10037575 Term: Pustular psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 16.1 Level: LLT Classification code 10037158 Term: Psoriasis palm & soles System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB CAS Number: 1229022-83-6 Other descriptive name: SECUKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Spain;Belgium;Poland;Austria;Russian Federation;Germany;United Kingdom;Italy;Sweden | |||
| 19 | NCT01952015 | August 21, 2013 | 25 March 2019 | Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis | Psoriasis | Biological: Secukinumab | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 12 | Phase 3 | Japan | |
| 20 | JPRN-JapicCTI-132305 | 01/8/2013 | 2 April 2019 | Study to assess the efficacy, safety and tolerability of secukinumab in Japanese subjects with GPP | A multi-center, open label study of subcutaneous secukinumab in prefilled syringes as mono- or co-therapy to assess the efficacy, safety and tolerability up to 52 weeks in Japanese subjects with generalized pustular psoriasis | Generalized Pustular Psoriasis (GPP) | Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose) Control intervention name : null | Novartis Pharma K.K. | 18 | BOTH | Phase 3 | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT01794117 | July 1, 2013 | 22 October 2019 | Anakinra for Inflammatory Pustular Skin Diseases | A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms | Sneddon-Wilkinson;Acrodermatitis Continua of Hallopeau;Pustular Psoriasis;Palmoplantar Pustulosis | Drug: Anakinra | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 18 Years | 110 Years | All | 18 | Phase 2 | United States | |
| 22 | JPRN-JapicCTI-132057 | 01/2/2013 | 2 April 2019 | An open-label, non-controlled study of KHK4827 in subjects with psoriasis | A Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null | Kyowa Hakko Kirin Co., Ltd. | 18 | BOTH | Phase 3 | |||||
| 23 | NCT01782937 | February 2013 | 2 March 2015 | An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis | A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Drug: KHK4827 | Kyowa Hakko Kirin Company, Limited | Not recruiting | 18 Years | N/A | Both | 30 | Phase 3 | Japan | |
| 24 | NCT01680159 | July 2012 | 16 December 2017 | A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis | Plaque Psoriasis;Psoriatic Arthritis;Pustular Psoriasis (Excluding a Localized);Psoriatic Erythroderma | Drug: TA-650 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 16 Years | 75 Years | All | 51 | Phase 3 | Japan | ||
| 25 | ChiCTR-TRC-12003542 | 2011-08-01 | 18 April 2017 | A Multi-center, randomized, double-blinded, double-dummy, parallel-controlled clinical trial to determine the efficacy and safety of Tripterygium Glycosides and Acitretin in patients with generalized pustular psoriasis | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Generalized pustular psoriasis | TG treatment group:Take TG tablet 2 slices every time, thrice a day, the placebo of Acitretin Capsules 2 pills every time, twice a day;Acitretin treatment group:Take the placebo of TG tablet 2 slices every time, thrice a day, Acitretin Capsules 2 pills every time, twice a day; | Institute of dermatology, Chinese Academy of Medical Sciences | Not Recruiting | 16 | 75 | Both | TG treatment group:180;Acitretin treatment group:180; | Post-market | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT01091051 | March 2010 | 19 February 2015 | Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis | Safety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis | Palmo-Plantar Pustular Psoriasis;Palmo-Plantar Pustulosis | Drug: Ustekinumab;Drug: Placebo (Soduim Chloride) | Innovaderm Research Inc. | Janssen-Ortho LLC | Not recruiting | 18 Years | N/A | Both | 33 | Phase 3 | Canada |
| 27 | EUCTR2007-003922-70-DE | 28/11/2007 | 19 March 2012 | Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Study | Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Study | moderate to severe palmoplantar pustular psoriasis MedDRA version: 9.1 Level: LLT Classification code 10037159 Term: Psoriasis pustular | Trade Name: Raptiva Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: Efalizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- | Technische Universität Dresden | Not Recruiting | Female: yes Male: yes | 42 | Phase 2a | Germany | |||
| 28 | EUCTR2006-005344-83-DE | 09/02/2007 | 19 March 2012 | A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98 | A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98 | Psoriasis is a common inherited autoimmune disease that affects 2-3% of the world-wide population. There are several recognized forms of psoriasis, such as plaque psoriasis, which is also known as psoriasis vulgaris and guttate, inverse, erythrodermic and pustular psoriasis, which can coexist within the same patient. The most common form is the plaque psoriasis. MedDRA version: 8.1 Level: LLT Classification code 10037153 Term: Psoriasis | Product Name: P32/98 3% Product Code: P32/98 Pharmaceutical Form: Cream CAS Number: 251572-86-8 Current Sponsor code: P32/98 Concentration unit: % percent Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Topical use (Noncurrent) Trade Name: Silikis 3µg/g Salbe Pharmaceutical Form: Ointment INN or Proposed INN: Calcitriol Concentration unit: µg/kg microgram(s)/kilogram Concentration type: equal Concentration number: 3000- | Probiodrug AG | Not Recruiting | Female: yes Male: yes | Germany | |||||
| 29 | NCT00301002 | June 2005 | 19 February 2015 | Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92) | Psoriasis;Palmoplantaris Pustulosis;Pustular Psoriasis of Palms and Soles;Pustulosis Palmaris et Plantaris;Pustulosis of Palms and Soles | Drug: Alefacept | The Guenther Dermatology Research Centre | Biogen Idec | Not recruiting | 18 Years | N/A | Both | 15 | Phase 2 | Canada |